We are live on ! Find out more
KALA icon

KALA BIO

97 hedge funds and large institutions have $171M invested in KALA BIO in 2021 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 37 increasing their positions, 14 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

164% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 14

56% more call options, than puts

Call options by funds: $2.74M | Put options by funds: $1.76M

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0% less ownership

Funds ownership: 0.02%0.02% (-0%)

8% less funds holding

Funds holding: 10697 (-9)

31% less capital invested

Capital invested by funds: $249M → $171M (-$77.5M)

38% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 24

Holders
97
Holders Change
-9
Holders Change %
-8.49%
% of All Funds
1.69%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
15
Increased
37
Reduced
14
Closed
24
Calls
$2.74M
Puts
$1.76M
Net Calls
+$978K
Net Calls Change
+$2.13M
Name Holding Trade Value Shares
Change
Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$57.6M
O
2
OrbiMed
New York
$29M
BlackRock
3
BlackRock
New York
$19.7M +$2.53M +161 +12%
Vanguard Group
4
Vanguard Group
Pennsylvania
$11.7M +$676K +43 +5%
CC
5
Caxton Corporation
New Jersey
$9.04M +$1.73M +110 +19%
State Street
6
State Street
Massachusetts
$4.36M +$770K +49 +18%
Geode Capital Management
7
Geode Capital Management
Massachusetts
$3.99M +$456K +29 +11%
SB
8
Samsara BioCapital
California
$3.19M
Northern Trust
9
Northern Trust
Illinois
$2.6M +$252K +16 +9%
Dimensional Fund Advisors
10
Dimensional Fund Advisors
Texas
$2.12M -$424K -27 -14%
PAMU
11
Pictet Asset Management (UK)
United Kingdom
$2.08M +$2.47M +157 New
UBS Group
12
UBS Group
Switzerland
$1.83M +$1.81M +115 +500%
Deutsche Bank
13
Deutsche Bank
Germany
$1.75M +$15.7K +1 +0.8%
KOCAA
14
Knights of Columbus Asset Advisors
Connecticut
$1.25M +$236K +15 +19%
Morgan Stanley
15
Morgan Stanley
New York
$1.18M +$723K +46 +107%
Brown Advisory
16
Brown Advisory
Maryland
$1.06M
Susquehanna International Group
17
Susquehanna International Group
Pennsylvania
$1.03M -$723K -46 -37%
ACM
18
ACT Capital Management
Pennsylvania
$1.01M +$1.19M +76 New
N
19
Nuveen
North Carolina
$963K -$645K -41 -36%
Bank of New York Mellon
20
Bank of New York Mellon
New York
$950K +$62.9K +4 +6%
PPA
21
Parametric Portfolio Associates
Washington
$928K +$204K +13 +23%
JAM
22
Jupiter Asset Management
United Kingdom
$920K
Goldman Sachs
23
Goldman Sachs
New York
$852K +$456K +29 +83%
Charles Schwab
24
Charles Schwab
California
$631K +$110K +7 +17%
Bank of America
25
Bank of America
North Carolina
$577K +$15.7K +1 +2%

KALA Hedge Fund Activity: Q2 2021 in Review

97 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in KALA BIO (KALA) for Q2 2021, worth a combined $171M — down 31% from $249M a quarter earlier.

Sellers outnumbered buyers: 24 funds closed out of KALA and 15 opened new positions — a net loss of 9 holders — while 14 trimmed existing stakes and 37 added.

The largest buyer was BlackRock, adding an estimated $2.53M. The largest seller was Eventide Asset Management, exiting entirely with an estimated $23.3M sold.

  • 97 institutional investors held KALA BIO (KALA) as of Q2 2021, down from 106 in Q1 2021.
  • Funds reported $171M of KALA BIO stock for Q2 2021, down 31% quarter-over-quarter.
  • 15 funds opened new KALA BIO positions in Q2 2021 and 24 closed out, a net change of -9 holders.
  • The largest KALA BIO buyer in Q2 2021 was BlackRock, an estimated $2.53M added.
  • The largest KALA BIO seller in Q2 2021 was Eventide Asset Management, an estimated $23.3M sold.

Based on aggregated 13F filings for Q2 2021.